The High-Value Target Scientific Committee will investigate and select potential antibody targets for discovery and deliberate on possible partnerships.
The committee’s term is set to last for three years, with the goal of establishing a strong pipeline and a network of partners.
Members include Ilse Roodink of ImmunoPrecise Europe, Zalan Szabo of Immuno-owned U-Protein Express, Andra Li of ImmunoPrecise Canada and ImmunoPrecise CEO Jennifer Bath. Additional members are expected to be added.
Talem Therapeutics is focused on the discovery of new antibodies, and plans to develop drug candidates related to neurology, immuno-oncology, gastroenterology, inflammation, and other rare diseases.
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel